Cancer

What it is

Cancer is a group of more than 100 diseases characterized by the uncontrolled growth and spread of abnormal cells. Treatment commonly combines surgery, chemotherapy, radiation, and increasingly targeted or immunotherapeutic agents. Symptom burden (pain, nausea, appetite loss, sleep disruption, anxiety) is substantial and often persists beyond active treatment.

Cancer is a qualifying condition under every comprehensive US medical cannabis program. It is one of the most common diagnoses for which patients enter state registries.

Cannabis and cannabis-derived therapies

The 2017 NASEM consensus report identified conclusive or substantial evidence that oral cannabinoids are effective antiemetics in adults receiving chemotherapy. Two FDA-approved synthetic cannabinoids (dronabinol and nabilone) are indicated for chemotherapy-induced nausea and vomiting (CINV) that has not responded to conventional antiemetics.

NASEM also found limited evidence of improvement in cancer-associated anorexia/cachexia (loss of appetite and body mass) with cannabinoid use, and limited evidence for sleep-disturbance improvement among cancer patients.

Antitumor effects of cannabinoids remain at the preclinical and early-clinical research stage. Cannabis is not a substitute for evidence-based cancer therapy, and patients should coordinate cannabis use with their oncology care team to avoid interactions with chemotherapy and immunotherapy regimens.

Symptom-specific evidence

Cancer patients commonly use cannabis for several distinct symptom domains. Evidence strength varies substantially:

Chemotherapy-induced nausea and vomiting (CINV)

Strongest evidence. NASEM substantial-evidence finding. Oral cannabinoids (dronabinol, nabilone) and inhaled cannabis have demonstrated efficacy in randomized controlled trials predating and overlapping the modern 5-HT3 antagonist (ondansetron, granisetron) and NK1 antagonist (aprepitant) classes. Modern combination antiemetic protocols are highly effective for most patients; cannabinoids are now most commonly used as breakthrough or refractory-CINV therapy. Dronabinol prescribing information directs administration 1-3 hours before chemotherapy with subsequent doses every 2-4 hours.

Cancer-related pain

Moderate evidence. The NASEM substantial-evidence finding for chronic pain in adults applies to cancer pain. Several controlled trials of nabiximols (Sativex) added to opioids have shown additive analgesic benefit for cancer pain not adequately controlled with opioids alone. NCCN clinical practice guidelines list cannabis as one option for breakthrough cancer pain.

Anorexia and cachexia

Limited evidence. Dronabinol is FDA-approved for AIDS-associated anorexia (different patient population) and has been studied in cancer-associated cachexia with mixed results. Patient-reported improvement in appetite is common; objective weight-gain effect in cancer cachexia is less consistent than in HIV-associated wasting.

Sleep disturbance

Moderate evidence. Cannabis and cannabinoids consistently improve sleep onset and reduce nighttime waking. Long-term effects on sleep architecture (REM suppression with chronic use) deserve consideration in patients using cannabis primarily for sleep.

Anxiety and mood

Limited evidence. Cancer-related anxiety and depression are common; cannabis effects are dose-dependent and individual. THC-dominant formulations can exacerbate anxiety at higher doses. CBD-dominant or balanced formulations are more commonly used for mood and anxiety in this population.

Treatment-related neuropathy

Moderate evidence. Chemotherapy-induced peripheral neuropathy is a major chronic complication of platinum agents, taxanes, vinca alkaloids, and bortezomib. The NASEM chronic-pain finding applies. Dedicated CIPN trials are sparse but observational data are positive.

Endocannabinoid pharmacology in oncology

The endocannabinoid system has multiple touchpoints with cancer biology:

• CB1 and CB2 receptors are expressed on many tumor cell types. Preclinical studies show cannabinoid-induced apoptosis, anti-angiogenesis, and anti-metastatic effects in various tumor models (glioma, breast, lung, prostate, pancreatic). Translation to human clinical benefit has not been demonstrated outside of small Phase I/II safety trials.
• Antiemetic action is mediated through CB1 receptors in the brainstem chemoreceptor trigger zone.
• Appetite stimulation is mediated through CB1 receptors in hypothalamic feeding circuits.
• Anti-inflammatory effects through CB2 receptors may have relevance for cancer-associated cachexia and immune-modulation contexts.

Cannabis-oncology interactions

Cannabis can interact with cancer therapy through several mechanisms:

• CYP450 enzyme inhibition and induction: cannabinoids (particularly CBD) inhibit CYP3A4, CYP2C9, CYP2C19, and CYP2D6. Many oral chemotherapy agents (tyrosine kinase inhibitors imatinib, erlotinib, dasatinib; PARP inhibitors; selected cytotoxics) are CYP3A4 substrates with narrow therapeutic windows. Cannabis use may elevate serum levels.
• Immunotherapy: observational data have suggested cannabis use may reduce checkpoint inhibitor response rates (immune-suppressive effect of THC on T-cell function). This is preliminary; patients on PD-1/PD-L1 inhibitors should discuss cannabis use with their oncologist.
• Anticoagulants: cancer patients on warfarin or DOACs face elevated bleeding risk from cannabis-mediated interactions.
• Opioids and benzodiazepines: additive CNS depression. Cancer-pain patients combining cannabis with high-dose opioids should monitor for sedation and respiratory effects.
• Antiemetics: combining cannabis with multiple other antiemetics (5-HT3 antagonists, NK1 antagonists, corticosteroids, olanzapine) requires sedation monitoring.

Pediatric oncology considerations

Children with cancer represent a special population. CBD (Epidiolex) is FDA-approved for specific pediatric epilepsy syndromes; THC-containing cannabis is not FDA-approved for any pediatric indication. State medical-cannabis programs permit pediatric cancer-patient enrollment in nearly all jurisdictions through caregiver designation. Pediatric oncology centers vary in their willingness to coordinate around cannabis use. Patients and families should discuss with the treating oncology team.

Survivorship considerations

Cancer survivors may continue cannabis use beyond active treatment for chronic pain (including neuropathy), sleep disturbance, anxiety, and fear of recurrence. Long-term cannabis use carries the same risks as in non-cancer populations (cannabis use disorder, respiratory effects of smoking, cognitive effects of acute intoxication) and additionally interacts with surveillance imaging and post-treatment monitoring in some contexts.

Practical guidance

• Coordinate cannabis use with the oncology team, particularly during active chemotherapy, immunotherapy, or radiation.
• Disclose cannabis use to all prescribers including the oncologist, primary care, and any pain-management or palliative-care team.
• Vaporization or oral preparations are generally preferred over smoking, particularly during chemotherapy-related immunosuppression.
• Start with low doses; titrate carefully given the polypharmacy context.
• Pre-surgical disclosure is important; cannabis can interact with anesthesia.
• Patients with hematologic malignancies (leukemia, lymphoma) or solid-organ transplant recipients face elevated infection risk from contaminated cannabis products; pharmaceutical-grade or rigorously tested medical-cannabis pharmacy products are preferred.

Related conditions

Cancer patients commonly experience symptoms covered by the mmjnow library as separate conditions: nausea (chemotherapy-induced nausea and vomiting), chronic-pain, peripheral-neuropathy, cachexia, anxiety-disorders, opioid-use-disorder (chronic-pain context), and terminal-illness (palliative-care context). Cross-reference each for additional clinical detail.